Reading ALDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALDX free→Reading ALDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALDX free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact ALDX's performance compared to its peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $1.76. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.95x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.13 → $-0.09 (+31.6% / 30d). 3 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 80% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$249.
How much price usually moves either way.
On a bad day, this stock has moved -$609.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,895.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will provide insights into revenue trends and overall financial health. This is crucial for assessing future growth potential.
Confirms one read:Earnings report shows revenue growth over 10% compared to last year. This shows strong performance.
Confirms the other:Earnings report shows revenue going down or staying the same. This raises concerns about growth.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ALDX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On June 9, 2026, following Aldeyra Therapeutics, Inc.’s (the “Company”) 2026 annual meeting of stockholders (the “2026 Annual Meeting”), and based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ALDX Aldeyra Therapeutics, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Why it matters: The health care sector is growing. Signs of revenue growth speeding up could help Aldeyra.
Confirms:Health care sector revenue growth shows signs of re-acceleration back toward previous highs.
Disproves:Revenue growth keeps slowing down. This shows ongoing challenges for the sector.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. (“Aldeyra”), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Mr. Joyce will continue to serve until his term expires at the 2026 Annual Meeting. The d…
Other Events. As previously disclosed, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into that certain Loan and Security Agreement, dated as of March 25, 2019, by and among the Company, Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”) and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders (as amended from time to time, the “Hercules…
of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response Letter. The 2026 Complete Response Letter stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate effica…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 23, 2025, Stephen G. Machatha, Ph.D. notified Aldeyra Therapeutics, Inc. (the “Company”) of his decision to voluntarily resign from his position as Chief Development Officer of the Company to pursue other professional opportunities. Dr. Machatha’s last day of employment with the Company will be on or before March 31, 2026 (such actual l…